ARS Pharmaceuticals (SPRY) Receivables - Other: 2021-2025
Historic Receivables - Other for ARS Pharmaceuticals (SPRY) over the last 3 years, with Sep 2025 value amounting to $4.3 million.
- ARS Pharmaceuticals' Receivables - Other rose 2708.55% to $4.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $4.3 million, marking a year-over-year increase of 2708.55%. This contributed to the annual value of $1.2 million for FY2024, which is 88.96% up from last year.
- Per ARS Pharmaceuticals' latest filing, its Receivables - Other stood at $4.3 million for Q3 2025, which was up 110.61% from $2.0 million recorded in Q2 2025.
- In the past 5 years, ARS Pharmaceuticals' Receivables - Other registered a high of $4.3 million during Q3 2025, and its lowest value of $122,000 during Q2 2024.
- In the last 3 years, ARS Pharmaceuticals' Receivables - Other had a median value of $349,000 in 2023 and averaged $960,091.
- In the last 5 years, ARS Pharmaceuticals' Receivables - Other plummeted by 65.04% in 2024 and then spiked by 2,708.55% in 2025.
- Over the past 5 years, ARS Pharmaceuticals' Receivables - Other (Quarterly) stood at $159,000 in 2021, then surged by 33.96% to $213,000 in 2022, then spiked by 206.10% to $652,000 in 2023, then spiked by 88.96% to $1.2 million in 2024, then spiked by 2,708.55% to $4.3 million in 2025.
- Its Receivables - Other was $4.3 million in Q3 2025, compared to $2.0 million in Q2 2025 and $963,000 in Q1 2025.